Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 1.00 |
| ▸ | FYN | P06241 | 13/20 | 0.91 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.71 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.71 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.71 |
| ▸ | JAK2 | O60674 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | INSR | P06213 | 1/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.71 |
| ▸ | CSF1R | P07333 | 1/20 | 0.71 |
| ▸ | LYN | P07948 | 1/20 | 0.71 |
| ▸ | RET | P07949 | 1/20 | 0.71 |
| ▸ | IGF1R | P08069 | 1/20 | 0.71 |
| ▸ | MET | P08581 | 1/20 | 0.71 |
| ▸ | ROS1 | P08922 | 1/20 | 0.71 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.71 |
| ▸ | FGR | P09769 | 1/20 | 0.71 |
| ▸ | KIT | P10721 | 1/20 | 0.71 |
| ▸ | SRC | P12931 | 1/20 | 0.71 |
| ▸ | BRAF | P15056 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234450 | 0.95 | FYN (1.00) | MKNK1FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL3041871 | 0.94 | FYN (0.88) | MKNK1FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL3036459 | 0.90 | MKNK1 (0.82) | MKNK1FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL3034186 | 0.88 | MKNK1 (0.78) | MKNK1FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL2946475 | 0.88 | FYN (0.79) | MKNK1FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL13234264 | 0.88 | FYN (0.78) | MKNK1FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL13223335 | 0.88 | MKNK1 (0.78) | MKNK1FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL16468585 | 0.88 | PIM1 (0.78) | MKNK1FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL3037765 | 0.87 | MKNK1 (0.77) | MKNK1FYNNTRK1NTRK3NTRK2 | |
| SCHEMBL1053535 | 0.86 | FYN (0.80) | MKNK1FYNNTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | claimed |
| US-9783543-B2 | Aminoimidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-10 | — | — | US | disclosed |
| US-9783543-B2 | Aminoimidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-10 | — | — | US | disclosed |
| US-9783543-B2 | Aminoimidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-10-10 | — | — | US | disclosed |
| EP-2920176-B1 | AMINOIMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2920176-B1 | AMINOIMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730929-B2 | Substituted aminoimidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| EP-2714692-B1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2017-03-22 | — | — | EP | disclosed |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-25 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-10 | — | — | US | disclosed |
| WO-2014076162-A1 | AMINOIMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-22 | — | — | WO | disclosed |
| EP-2723748-A1 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2014-04-30 | — | — | EP | disclosed |
| WO-2012175591-A1 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012175591-A1 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012163942-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-12-06 | — | — | WO | disclosed |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194430-A1 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES | CCND2, CCND1, VEGFA | MKNK1 3763/4885FYN 2261/4885NTRK1 1946/4885 |
| US-20140288069-A1 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS | MKNK1, MKNK2, MAP4K5 | MKNK1 1/4885FYN 884/4885NTRK1 447/4885 |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | MKNK1 816/4885FYN 3/4885NTRK1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.